Uncategorized

AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel

Published

1 week ago

on

The pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment of certain cancers.

The Chicago-area pharma giant has signed …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version